GlassScriptPhysician profile
Jyoti Rao
NPI 1841283389
$4,784.11
in general payments reported to CMS, 2019-2025
29 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $51.50 · 2021: $345 · 2022: $1,103 · 2023: $879 · 2024: $737 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.98 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $988.25 | 2019-2025 | |
| Janssen Biotech, INC. | $551.42 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $540.03 | 2019-2025 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $337.18 | 2019-2025 | Linzess |
| Merck Sharp & Dohme LLC | $318.53 | 2021-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $246.55 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $240.34 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $194.75 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.87 | 2019-2025 | Xifaxan, Relistor |
| Celgene Corporation | $158.06 | 2021-2023 | Zeposia |
| Mirum Pharmaceuticals, INC. | $150.00 | 2025 | Livmarli |
| Madrigal Pharmaceuticals | $141.06 | 2025 | Rezdiffra |
| Ardelyx, INC. | $118.70 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $115.59 | 2022-2023 | Suflave |
| Evoke Pharma, INC. | $93.47 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.33 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $64.52 | 2025 | Zenpep |
| Redhill Biopharma INC. | $53.16 | 2022 | |
| Pfizer INC. | $49.71 | 2023-2025 | |
| Medtronic, INC. | $28.22 | 2024 | Nexpowder |
| Fujifilm Healthcare Americas Corporation | $27.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.04 | 2023 | Dupixent |
| Axonics, INC. | $22.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.97 | 2023 | Rebyota |
| Allergan, INC. | $15.15 | 2019 | |
| Novo Nordisk INC | $13.67 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $13.58 | 2019 | |
| Cook Medical LLC | $11.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,834.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyoti Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.